U.S. flag

An official website of the United States government

GTR Home > Tests > +RNAinsight® for Penn Cancer Grant Panel

Performance Characteristics



  • Entire test performed in-house

Analytical Validity


This test is designed and validated to be capable of detecting >99% of described mutations in the gene(s) represented.


Not provided

Proficiency Testing (PT)

Is proficiency testing performed for this test? Help
PT ProviderHelp

FDA Regulatory Clearances of the Test

FDA Category Designation
FDA exercises enforcement discretion

Suggested reading

Practice guidelines

  • NCCN, 2023
    NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Colon Cancer, 2023
  • ACMG ACT, 2019
    American College of Medical Genetics and Genomics, Genomic Testing (Secondary Findings) ACT Sheet, APC Pathogenic Variants (Familial Adenomatous Polyposis [FAP]), 2019
  • ACMG ACT, 2012
    American College of Medical Genetics and Genomics Family History ACT Sheet, Colon Cancer (Asymptomatic), 2012
  • EuroGenetest, 2011
    Clinical utility gene card for: familial adenomatous polyposis (FAP) and attenuated FAP (AFAP).

IMPORTANT NOTE: NIH does not independently verify information submitted to the GTR; it relies on submitters to provide information that is accurate and not misleading. NIH makes no endorsements of tests or laboratories listed in the GTR. GTR is not a substitute for medical advice. Patients and consumers with specific questions about a genetic test should contact a health care provider or a genetics professional.